

Bereskin & Parr

INTELLECTUAL PROPERTY LAW

Manulife Corporate Park, 6733 Mississauga Road, Suite 600, Mississauga, Ontario L5N 6J5
Tel: 905.812.3600 Fax: 905.814.0031 www.bereskinparr.com

TORONTO MISSISSAUGA WATERLOO MONTREAL
FAX TRANSMITTAL

RECEIVED
CENTRAL FAX CENTER

AUG 12 2008

TO: Timothy P. Thomas
FIRM: United States Patent and Trademark Office
FROM: Patricia Folkins
FILE #: 10935-35
LAWYER #: 258

DATE: August 12, 2008

FAX #: 571-273-8300

PAGES: 43 (including cover sheet)

COMMENTS:

Please see attached Response to Office Action dated May 12, 2008.

If transmission is interrupted or of poor quality, please notify us immediately by calling
Hetel Patel at 6552.

CONFIDENTIAL

This communication may contain information that is privileged or confidential and is intended only for the use of the individual to whom it is addressed. Any other distribution, copying or disclosure is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us by mail. Thank you.

RECEIVED
CENTRAL FAX CENTER

002

AUG 12 2008

PTO/SB/97 (01-08)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

On August 12, 2008

Date



Signature

Patricia Folkins

Typed or printed name of person signing Certificate

51,379

Registration Number, if applicable

416 957 1683

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

1. Response to Office Action dated May 12, 2008 (12 pages)
2. Sengupta, Shantanu et al., "Albumin Thiolate Anion Is an Intermediate in the Formation of Albumin-S-S-Homocysteine" May 14, 2001 (7 pages)
3. Kuhlmann, Martin M., "Management of hyperphosphatemia" 2006 (8 pages)
4. Ventura, Paola et al., "Urinary and Plasma Homocysteine and Cysteine Levels during Prolonged Oral N-Acetylcysteine Therapy" 2002 (10 pages)
5. Friedman, Allon N et al., "The Effect of N-Acetylcysteine on Plasma, Total Homocysteine Levels in Hemodialysis: A Randomized, Controlled Study" February 2003. (5 pages)

Bereskin & Parr

INTELLECTUAL PROPERTY LAW

Application No. 10/596,479

Response dated: August 12, 2008

Response to Office Action dated: May 12, 2008

RECEIVED
CENTRAL FAX CENTER

AUG 12 2008

Appl. No : ~~10/543,388~~ 10/596,479 Confirmation No.: 7049
Applicants : Urquhart et al.
Filed : March 29, 2007
Title : Method of Treating Elevated Plasma Homocysteine Levels in
ESRD Patients
TC./A.U. : 1614
Examiner : Timothy P. Thomas

Docket No. : 10935-35
Customer No. : 001059

Honorable Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia
22313-1450

RESPONSE

Sir:

The present letter is filed in response to the Office Action dated May 12, 2008.
Accordingly, the Response is timely filed.

Amendments to the Abstract begin on page 2 of this paper.

Amendments to Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begin on page 4
of this paper.

Remarks/Arguments begin on page 6 of this paper.

Manulife Corporate Park, 6733 Mississauga Road, Suite 600, Mississauga, Ontario L5N 6J5
Tel: 905.812.3600 Fax: 905.814.0031 www.bereskinparr.com

TORONTO MISSISSAUGA WATERLOO MONTREAL